Philogen is open to partnerships that are in line with the company’s corporate strategy to continue the development of its preclinical and clinical programs and to establish the commercialization of its late-stage clinical assets.
Philogen offers collaborations based on its proprietary tumor-targeting platforms and will selectively choose to partner with companies that have therapeutic expertise in relevant disease areas and a significant commitment to the development and commercialization of biologics.
For collaboration opportunities, partnerships, or licensing agreements, please contact:
Dr. Christian Lizak
Head of Business Development
Read more
Christian Lizak, Ph.D.
Head of Business Development
Christian as responsible for Business Development activities at Philogen. He graduated in Biochemistry from the Technical University of Munich and obtained his Ph.D. from ETH Zurich in 2011. His dissertation was awarded the Silver Medal of ETH. Christian performed postdoctoral research at ETH Zurich and at the University of British Columbia in Vancouver. His research resulted in several publications including in Nature and he received the Young Investigator Award of the International Carbohydrate Society.
Before joining Philogen in 2018, Christian held a leadership role in vaccine development at LimmaTech Biologics AG and he previously worked at Roche and MorphoSys.
Christian Lizak, Ph.D.
Head of Business Development
Christian as responsible for Business Development activities at Philogen. He graduated in Biochemistry from the Technical University of Munich and obtained his Ph.D. from ETH Zurich in 2011. His dissertation was awarded the Silver Medal of ETH. Christian performed postdoctoral research at ETH Zurich and at the University of British Columbia in Vancouver. His research resulted in several publications including in Nature and he received the Young Investigator Award of the International Carbohydrate Society.
Before joining Philogen in 2018, Christian held a leadership role in vaccine development at LimmaTech Biologics AG and he previously worked at Roche and MorphoSys.
Collaboration on DNA-encoded chemical library platform
Philogen´s Swiss subsidiary Philochem has pioneered the development of the DNA-encoded library (DEL) technology, which opens new possibilities for drug discovery in a fast and cost-effective way. Philochem owns proprietary technologies and large DNA-encoded chemical libraries containing more than one billion compounds. For more information, please visit Philochem.
Philochem offers flexible collaboration structures, adjusted to the requirements of the partner, for the screening of binders against few or several targets of choice.
Collaboration on GMP manufacturing
Philogen offers customized activities for cell line development and GMP manufacturing of biotherapeutics to selected industrial and academic partners in the frame of collaborations. Using Philogen´s GMP manufacturing plant in Montarioso near Siena, Italy, we produce GMP-grade drug products to the highest regulatory standards that can be used for up to Phase III clinical trials
A wealth of partnerships validate Philogen’s approach and science
Philogen has signed collaboration and/or licensing agreements with large pharmaceutical companies including AbbVie, Bayer, Boehringer Ingelheim, Celgene (a subsidiary of Bristol-Myers Squibb), Janssen Biotech, Inc. (a Johnson & Johnson company), MedImmune (a wholly owned subsidiary of AstraZeneca), Merck-Serono, Novartis, Pfizer, Schering and Servier
Our collaboration agreements with academic institutions include ETH Zurich, Scripps Research, The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), University of Zurich and Wyss Translational Center Zurich